Msln targeting trispecific proteins and methods of use
AssigneeHarpoon Therapeutics, Inc.
InventorsHolger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
Life of this patent
Estimating the term…
Abstract
Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.
Claims32
1-27. (canceled)
A method for the treatment or amelioration of proliferative disease, or a tumorous disease, comprising administration of a mesothelin (MSLN) binding trispecific protein comprising a sequence as set forth in any one of SEQ ID Nos.:
- 58-86, 98, 100, and 101.
A method for the treatment or amelioration of proliferative disease, or a tumorous disease, comprising administration of a mesothelin (MSLN) binding trispecific protein comprising a sequence as set forth in SEQ ID No.:
- 98.
Dependencies are inferred from the claim text.